Notícias e Atividades da Palatin Technologies
Presença
Palatin Technologies é uma empresa listada sob o símbolo PTN (US).
Executivos
Veja o organograma con seus 15 executivos principais
Biografias mais buscadas da Palatin Technologies
- Carl Spana, President, Chief Executive Officer and Director
- John Prendergast, Chairman of the Board
- Anthony Manning, Director
Criar um alerta
para seguir os movimentos de executivos da Palatin Technologies.
Biotecnologia
Palatin Technologies possui 2.347 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnologia
- Biolinq acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 23 de abril de 2025).
- Glycomine acaba de anunciar uma arrecadação de fundos de 115 milhões de dólares. (publicado em 22 de abril de 2025).
- Attovia Therapeutics acaba de anunciar uma arrecadação de fundos de 90 milhões de dólares. (publicado em 21 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Palatin Technologies
- Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Palatin Technologies
- Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds | Palatin Technologies
- Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis | Palatin Technologies
- Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results | Palatin Technologies
- Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 | Palatin Technologies
- Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 | Palatin Technologies
- Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity | Palatin Technologies
- Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium | Palatin Technologies
- Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium | Palatin Technologies
- Palatin Receives Notice of Non-Compliance from NYSE American | Palatin Technologies
- View more press releases Close
Redes sociais sobre Palatin Technologies
- Palatin Technologies na Wikipedia, Google News e Yahoo Finance
- Palatin Technologies na LinkedIn, Twitter e YouTube
